EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Cost effectiveness of hepatitis C direct acting agents

Akshay Shetty, Michelle Lee, Julia Valenzuela, Sammy Saab

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2024.2348053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Akshay Shetty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Cost-Benefit Analysis, Hepatitis C, Chronic, Genotype. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Introduction of direct acting antivirals (DAA) has transformed treatment of chronic hepatitis C (HCV) and made the elimination of HCV an achievable goal set forward by World Health Organization by 2030. Multiple barriers need to be overcome for successful eradication of HCV. Availability of pan-genotypic HCV regimens has decreased the need for genotype testing but maintained high efficacy associated with DAAs. AREAS COVERED: In this review, we will assess the cost-effectiveness of DAA treatment in patients with chronic HCV disease, with emphasis on general, cirrhosis, and vulnerable populations. EXPERT OPINION: Multiple barriers exist limiting eradication of HCV, including cost to treatment, access, simplified testing, and implementing policy to foster treatment for all groups of HCV patients. Clinically, DAAs have drastically changed the landscape of HCV, but focused targeting of vulnerable groups is needed. Public policy will continue to play a strong role in eliminating HCV. While we will focus on the cost-effectiveness of DAA, several other factors regarding HCV require on going attention, such as increasing public awareness and decreasing social stigma associated with HCV, offering universal screening followed by linkage to treatment and improving preventive interventions to decrease spread of HCV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCost-Benefit AnalysisHepatitis C, ChronicGenotypeHumansHealth Services AccessibilityVulnerable PopulationsLiver CirrhosisHealth PolicyHepacivirusMass ScreeningCost-Effectiveness Analysis

Stichwörter der Autor:innen

Hepatitis Cantiviral therapycost effectivenessdirect acting agentshepatitis c elimination

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
  • Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.

Zitieren

APA

Shetty, A., Lee, M., Valenzuela, J., & Saab, S. (2024). Cost effectiveness of hepatitis C direct acting agents. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2348053

Vancouver

Shetty A, Lee M, Valenzuela J, Saab S. Cost effectiveness of hepatitis C direct acting agents. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2348053

BibTeX
@article{Shetty2024,
  author = {Shetty, Akshay and Lee, Michelle and Valenzuela, Julia and Saab, Sammy},
  title = {Cost effectiveness of hepatitis C direct acting agents},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2024.2348053}
}
Kostenlos starten →